The Pharmaceutical Industry in Mexico

The pharmaceutical industry engages in the research, development, production and sale of chemical products or bio-drugs used for disease prevention or treatment. Drugs, vaccines and antiserums, vitamins, pharmaceutical preparations for veterinary use, and other products comprise the industry.

It is estimated that the industry in Mexico produced 9.6 billion dollars in 2016.

In 2016, Mexican pharmaceutical exports reached 1.4 billion dollars, making Mexico the leading exporter in Latin America.

The main export destinations were the United States, Panama and Colombia, with shares in total Mexican exports from the industry of 21%, 14% and 7%, respectively.

Among the products that were most exported are medicines for prophylactic or therapeutic use, other antisera and products that contain vitamins.

Companies Established in Mexico

According to INEGI, there are 793 economic units in Mexico that specialize in the pharmaceutical industry. They are located mainly in Mexico City, Jalisco, Estado de México, Puebla and Morelos.

Twenty of the 25 top international pharmaceutical companies have presence in Mexico, such as Bayer, Pfizer, MSD, Grupo Novartis México, GlazoSmithKline, Merck, Boehringer Ingelheim, Shering Plough, Aztrazeneca, Baxter and Elli Lilly Company.

Foreign Direct Investmen

The pharmaceutical industry recorded an accumulated investment of 4.8 billion dollars in the 2010-2016 period.

Mexico's Strengths in the Pharmaceutical Industry

Market Size. The Mexican pharmaceutical market is the second largest in Latin America. In 2016 alone, the Mexican population consumed 13.6 billion dollars in pharmaceuticals.

Manufacturing Costs. KPMG's study Competitive Alternatives 2016 shows that Mexico offers savings of 17.1% in manufacturing costs in the pharmaceutical industry compared to the United States.

Regulations. Mexico is one of the most developed markets in Latin America in terms of regulations; the Federal Commission for the Protection Against Health Risks (COFEPRIS) has been recognized by the Pan-American Health Organization as a health regulatory, control and promotion authority in Mexico.

Export Platform. Mexico's location enables considerable savings in logistics and close monitoring of the manufacturing process, facilitates plant inspection by health authorities and allows rapid response to sudden changes in demand trends.

Regulations. Mexico is one of the most developed markets in Latin America in terms of regulations; the Federal Commission for the Protection Against Health Risks (COFEPRIS) has been recognized by the Pan-American Health Organization as a health regulatory, control and promotion authority in Mexico.

Export Platform. Mexico's location enables considerable savings in logistics and close monitoring of the manufacturing process, facilitates plant inspection by health authorities and allows rapid response to sudden changes in demand trends.

Manufacturing Costs. KPMG's study Competitive Alternatives 2016 shows that Mexico offers savings of 17.1% in manufacturing costs in the pharmaceutical industry compared to the United States.

 

    Economic Units

    Graduates from Pharmaceutical and Pharmacy Programs*

    Download

     

    Success stories

    Novartis

    Novartis México, a pharmaceutical company from Switzerland invested in 2017 about 10 million dollars in research and development, in accordance with its commitment 2015-2020 of achieving 50 million dollars invested in the country. The projects include the final phases of the upcoming launchings in Oncology and Migraine. Mexico will be the support center for the Americas, including the United States.

    Pfizer

    In 2017, the North American pharmaceutical Company, informed about its investment of 9.3 million dollars for the plant at Toluca, Estado de México. The project will include new production lines and a packaging line.